



Mithra's EGM Approves Warrant Plan for LDA Capital

Liege, Belgium, 23 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that the Company's Extraordinary General Meeting (EGM) held on 22 July 2020 approved the issuance of 690,000 warrants for the benefit of LDA Capital Ltd. The warrants were issued as part of the transaction announced on April 24 2020.¹

The warrants have a term of three years. They are generally not transferable and may only be exercised in accordance with the terms and conditions approved by the EGM. Each warrant gives the right to subscribe for one new Mithra share. Should the warrants be exercised, Mithra will apply for the listing of the resulting new shares on Euronext Brussels. The warrants will not be listed on any stock exchange market.

Since the attendance quorum for the proposed issuance of the Share Lending Warrants for the benefit of, respectively, François Fornieri, Alychlo NV, Noshag SA was not reached (as far as needed in accordance with article 7:193 of the Belgian Companies and Associations Code), Mithra will convene shortly a new EGM.

Mithra's total share capital currently amounts to EUR 31,153,882.82 divided in 42,554,297 ordinary shares. All documents relating to the General Meeting, including the terms and conditions of the warrants, are available on the [Company's website](#).

For more information, please contact:

Alexandra Deschner (IRO) : +32 490 58 35 23 - investorrelations@mithra.com

Carole Kousis (Press) : +32 4 349 28 22 - press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com

¹ [Presse release Mithra](#), 24/04/2020

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

A circular teal icon with the text "News Alerts" in white, positioned to the left of the social media information.

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)